89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 11:20 AM EDT, along with one-on-one investor meetings. The presentation will be available via webcast through 89bio's investor relations website, with replay access for approximately 30 days after the event.

News Market Reaction

-0.99%

1 alert

-0.99% News Effect

On the day this news was published, ETNB declined 0.99%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company’s Management will participate in a fireside chat at the Goldman Sachs 46^th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 11:20 AM EDT and participate in one-on-one investor meetings.

The webcast of the fireside chats will be accessible in the investor section of 89bio’s website. A replay of the webcasts will be available for approximately 30 days following each conference.

About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.

Investor Contact: 
Annie Chang 
89bio, Inc.
investors@89bio.com

PJ Kelleher
LifeSci Advisors, LLC
617-430-7579
pkelleher@lifesciadvisors.com

Media Contact: 
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com

FAQ

When is 89bio (ETNB) presenting at the Goldman Sachs Healthcare Conference 2025?

89bio will participate in a fireside chat on Wednesday, June 11, 2025 at 11:20 AM EDT.

Where can I watch 89bio's (ETNB) Goldman Sachs conference presentation?

The webcast will be available in the investor section of 89bio's website, with replay access for approximately 30 days following the conference.

What is 89bio's (ETNB) main business focus?

89bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for liver and cardiometabolic diseases.

Will 89bio (ETNB) hold individual investor meetings at the Goldman Sachs conference?

Yes, 89bio's management will participate in one-on-one investor meetings during the conference.